Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 10/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | TAF1 | P21675 | 1/20 | 0.31 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.31 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4241759 | 0.81 | SLC6A9 (0.36) | OPRD1KDM4ECYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4238321 | 0.81 | SLC6A9 (0.36) | OPRD1KDM4ECYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4243962 | 0.76 | OPRD1 (0.34) | OXTROPRD1OPRM1OPRK1OPRL1 | |
| SCHEMBL3711687 | 0.76 | SLC6A9 (0.43) | OXTR | |
| SCHEMBL7899357 | 0.76 | MAPT (0.43) | OXTR | |
| SCHEMBL2124777 | 0.75 | SLC6A9 (0.49) | CYP2C9 | |
| SCHEMBL4239283 | 0.74 | SLC6A9 (0.50) | — | |
| SCHEMBL4241807 | 0.74 | SLC6A9 (0.50) | — | |
| SCHEMBL4249594 | 0.74 | SLC6A9 (0.50) | — | |
| SCHEMBL7894548 | 0.73 | OPRD1 (0.32) | OXTROPRD1OPRM1OPRK1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090030033-A1 | Novel Compounds 894 | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030033-A1 | Novel Compounds 894 | AZI2, TPMT, AMPD2 | OXTR 1183/4885OPRD1 3153/4885OPRM1 2971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.